HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case

Rhea-AI Filing Summary

HUTCHMED (China) Limited reports an update concerning its Chairman and Non-executive Director, Dr Dan Eldar, under AIM Rule 17 Schedule 2(g). A former directorship held by Dr Eldar at S.D. Sight Diagnostics Ltd., an Israeli private medical device company, became relevant after that company entered insolvency proceedings in Israel.

Applications for insolvency proceedings for S.D. Sight were filed on 12 April 2026, with an order commencing proceedings issued on 24 May 2026 and a trustee appointed on 28 May 2026. Public information indicates proceedings involve about NIS3,057,876 (approximately US$1,019,292). Dr Eldar served as a director of S.D. Sight from 20 December 2018 to 18 March 2026, nominated by Hutchison Water Israel E.P.C Ltd, which invested about 9.98% in S.D. Sight.

HUTCHMED states that neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is part of the HUTCHMED Group, and the insolvency proceedings do not involve the Group or its businesses. The board expresses the view that this has no impact on the Group’s businesses and operations, and discloses the matter solely as a change of information regarding Dr Eldar.

Filing Explained

The separate S.D. Sight insolvency proceedings remained ongoing as of August 18, 2026, and HUTCHMED said their outcome was not known, so the disclosure does not establish a completed resolution.

Key Figures

Insolvency amount (NIS): NIS3,057,876 Insolvency amount (USD equivalent): US$1,019,292 Hutchison Water Israel stake in S.D. Sight: 9.98% +5 more

8 metrics

Insolvency amount (NIS) NIS3,057,876 Amount involved in S.D. Sight insolvency based on public information

Insolvency amount (USD equivalent) US$1,019,292 Approximate USD equivalent of NIS3,057,876

Hutchison Water Israel stake in S.D. Sight 9.98% Investment in S.D. Sight by Hutchison Water Israel E.P.C Ltd

Eldar directorship start 20 December 2018 Date Dr Eldar became a director of S.D. Sight

Eldar directorship end 18 March 2026 Date Dr Eldar ceased to be a director of S.D. Sight

Insolvency application date 12 April 2026 Date application for commencement of insolvency proceedings was filed

Order commencing proceedings 24 May 2026 Date Tel Aviv-Jaffa District Court issued order commencing insolvency proceedings

Trustee appointment date 28 May 2026 Date a trustee was appointed in S.D. Sight insolvency

Key Terms

AIM Rules, Rule 17 Schedule 2(g), insolvency proceedings, trustee, +1 more

5 terms

AIM Rules regulatory

"provides the following update pursuant to Rule 17 Schedule 2(g) of the AIM Rules"

AIM Rules are the set of regulatory requirements that govern companies listed on the AIM market of the London Stock Exchange, outlining what firms must disclose, how they must behave, and the standards for admission and ongoing trading. For investors, they matter because they set expectations for transparency and accountability—like a rulebook that helps you judge how reliably a small or growing company shares material information and manages risks, which affects investment trust and valuation.

Rule 17 Schedule 2(g) regulatory

"update pursuant to Rule 17 Schedule 2(g) of the AIM Rules for Companies"

insolvency proceedings regulatory

"had become subject to insolvency proceedings in Israel"

A formal legal process used when a company cannot pay its debts, where a court oversees how the company’s assets and obligations are handled — either by reorganizing the business to keep it operating or by selling assets to pay creditors. For investors this matters because it determines who gets paid first and how much, often reducing or wiping out shareholders’ value while giving higher priority to lenders, and it sets the timeline and likelihood of any recovery.

trustee regulatory

"an order for commencement of proceedings on 24 May 2026, and a trustee appointed"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Insolvency Proceedings Commissioner regulatory

"public information made available by the Insolvency Proceedings Commissioner in Israel"

FAQ

What event did HUTCHMED (HCM) disclose regarding Dr Dan Eldar on this Form 6-K?

HUTCHMED disclosed that a former directorship held by Dr Dan Eldar became relevant because S.D. Sight Diagnostics Ltd., where he was a director until 18 March 2026, entered insolvency proceedings in Israel, triggering disclosure under AIM Rule 17 Schedule 2(g).

Does the S.D. Sight insolvency affect HUTCHMED (HCM) or its group businesses?

HUTCHMED states the insolvency proceedings do not involve the Group or its businesses. The board is of the opinion that the situation has no impact on the Group’s businesses and operations and is disclosed only as updated information on Dr Eldar.

What are the key dates of the S.D. Sight insolvency mentioned by HUTCHMED (HCM)?

An application for insolvency proceedings was filed on 12 April 2026, an order commencing proceedings issued on 24 May 2026, and a trustee appointed on 28 May 2026. These dates frame the formal start and oversight of S.D. Sight’s insolvency process.

What is the size of the claim in S.D. Sight’s insolvency noted by HUTCHMED (HCM)?

HUTCHMED cites public information that the amount involved in S.D. Sight’s proceedings is about NIS3,057,876, equivalent to approximately US$1,019,292. This figure comes from the Insolvency Proceedings Commissioner in Israel and reflects the proceedings’ monetary scale.

What was Dr Dan Eldar’s role and tenure at S.D. Sight according to HUTCHMED (HCM)?

HUTCHMED reports that Dr Dan Eldar served as a director of S.D. Sight from 20 December 2018 to 18 March 2026. He was nominated by Hutchison Water Israel E.P.C Ltd, which invested about 9.98% in S.D. Sight and with which he is an executive director.

Are S.D. Sight or Hutchison Water Israel E.P.C Ltd part of the HUTCHMED (HCM) Group?

HUTCHMED clarifies that neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is a member of the Group. They are separate entities, and the disclosure is made solely to comply with AIM Rule 17 Schedule 2(g) regarding changes in information about a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/18/2026 - 06:12 AM Accepted by SEC EDGAR 08/18/2026 - 06:12 AM Learn about SEC filing dates

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of August 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Announcement pursuant to AIM Rule 17 Schedule 2(g) update ​
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: August 18, 2026

3

Exhibit 99.1

​

​

Announcement pursuant to AIM Rule 17 Schedule 2(g) Update

​

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, August 18, 2026: HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX:13) (the “Company”, together with its subsidiaries, the “Group”) today provides the following update pursuant to Rule 17 Schedule 2(g) of the AIM Rules for Companies (the “AIM Rules”).

​

The board of directors of the Company (the “Board”) was notified by Dr Dan Eldar, Chairman and Non-executive Director of the Company, that S.D. Sight Diagnostics Ltd. (“S.D. Sight”), a company of which Dr Eldar was formerly a director, had become subject to insolvency proceedings in Israel.

​

As the Company understands, S.D. Sight is an Israeli private company incorporated in Tel Aviv, Israel and is a medical device company developing a platform for diagnosing blood diseases using computer vision technology. Dr Eldar was a director of S.D. Sight from 20 December 2018 to 18 March 2026. Hutchison Water Israel E.P.C Ltd, of which Dr Eldar is an executive director, made an investment of approximately 9.98% in S.D. Sight and nominated Dr Eldar as a director to the board of S.D. Sight.  Neither Hutchison Water Israel E.P.C Ltd nor S.D. Sight is a member of the Group.

​

Based on the information available to the Company, an application for commencement of insolvency proceedings in respect of S.D. Sight was filed on 12 April 2026, with the Tel Aviv-Jaffa District Court issuing an order for commencement of proceedings on 24 May 2026, and a trustee appointed on 28 May 2026. The insolvency proceedings remained ongoing. The outcome of the proceedings is not known to the Company as at the date of this announcement.

​

The amount involved in the proceedings, based on public information made available by the Insolvency Proceedings Commissioner in Israel, is approximately NIS3,057,876 (equivalent to approximately US$1,019,292).

​

As the commencement of the insolvency proceedings in respect of S.D. Sight and the appointment of the trustee occurred within 12 months after Dr Eldar ceased to act as a director of S.D. Sight, the above information is disclosed by the Company pursuant to Rule 17 Schedule 2(g) of the AIM Rules, as a change of information regarding Dr Eldar.

​

As the insolvency proceedings do not involve the Group or its businesses, the Board is of the opinion that it does not have any impact on the businesses and operations of the Group.

​

Save as disclosed above, there is no other information concerning the above change that needs to be brought to the attention of the shareholders of the Company.

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
​	​
Media Enquiries	​
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
​	​
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
​	​
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
​	​
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

​

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 16.4 KB